董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian Murphy | 男 | Chief Executive Officer and Director | 66 | 40.88万美元 | 未持股 | 2023-05-01 |
| Christopher Fashek | 男 | Chairman of the Board | 72 | 18.98万美元 | 未持股 | 2023-05-01 |
| Martin Goldstein | 男 | Director | 54 | 3.44万美元 | 未持股 | 2023-05-01 |
| Michael Ferguson | 男 | Director | 51 | 3.96万美元 | 未持股 | 2023-05-01 |
| Aurora Cassirer | 女 | Director | 71 | 0.95万美元 | 未持股 | 2023-05-01 |
| Maria Schroeder | 女 | Director | 64 | 0.95万美元 | 未持股 | 2023-05-01 |
| Thomas R. Mika | 男 | Director | 71 | 4.13万美元 | 未持股 | 2023-05-01 |
| Harold Jacob | 男 | Chief Medical Officer and Director | 69 | 3.44万美元 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian Murphy | 男 | Chief Executive Officer and Director | 66 | 40.88万美元 | 未持股 | 2023-05-01 |
| Stephen Brown | 男 | Chief Financial Officer | 67 | 29.86万美元 | 未持股 | 2023-05-01 |
| Harold Jacob | 男 | Chief Medical Officer and Director | 69 | 3.44万美元 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- Brian Murphy
-
Brian Murphy自2016年10月起担任我们的首席执行官兼董事。Murphy先生在医疗设备和医疗技术公司拥有超过25年的高级销售，运营和一般管理经验，包括ATI Medical Equipment Corporation，Mountain Medical Equipment Inc.和Healthdyne Technologies Inc.。从2012年到2016年，墨菲先生在MimedxGroup，Inc.担任过各种职务，在那里他发起并管理高级伤口护理部门的商业销售和国民账户工作。Murphy从2010年到2012年担任O2Insights，Inc.（一家初创伤口护理诊断公司）首席执行官，2012年6月领导公司出售给Systegenix Ltd.。Murphy从2008年到2010年担任Convatec销售Vice President，领导负压伤口治疗业务。从1992年到2008年，墨菲先生在KineticConcepts，Inc.总共服务了17年KCI担任多个职位，监督销售、运营和综合管理。Murphy先生持有南伊利诺伊大学（Southern Illinois University）通信文学学士学位。
Brian Murphy,has served as Nanovibronix, Inc. chief executive officer and director since October 2016. Mr. Murphy has over 25 years of senior sales, operations and general management experience in medical device and medical technology companies, including ATI Medical Equipment Corporation, Mountain Medical Equipment Inc. and Healthdyne Technologies Inc. From 2012 to 2016, Mr. Murphy served in various roles at MiMedx Group, Inc., where he initiated and managed the commercial sales and national accounts efforts within the advanced wound care segment. From 2010 to 2012, Mr. Murphy was the chief executive officer of O2 Insights, Inc., a start-up wound care diagnostics company, and led the sale of the company to Systagenix Ltd. in June 2012. From 2008 to 2010, Mr. Murphy served as vice president of sales for ConvaTec and led the negative pressure wound therapy business. From 1992 to 2008, Mr. Murphy served a total of 17 years at Kinetic Concepts, Inc. (KCI) in various positions overseeing sales, operations and general management. Mr. Murphy holds a bachelor of arts degree in communications from Southern Illinois University. - Brian Murphy自2016年10月起担任我们的首席执行官兼董事。Murphy先生在医疗设备和医疗技术公司拥有超过25年的高级销售，运营和一般管理经验，包括ATI Medical Equipment Corporation，Mountain Medical Equipment Inc.和Healthdyne Technologies Inc.。从2012年到2016年，墨菲先生在MimedxGroup，Inc.担任过各种职务，在那里他发起并管理高级伤口护理部门的商业销售和国民账户工作。Murphy从2010年到2012年担任O2Insights，Inc.（一家初创伤口护理诊断公司）首席执行官，2012年6月领导公司出售给Systegenix Ltd.。Murphy从2008年到2010年担任Convatec销售Vice President，领导负压伤口治疗业务。从1992年到2008年，墨菲先生在KineticConcepts，Inc.总共服务了17年KCI担任多个职位，监督销售、运营和综合管理。Murphy先生持有南伊利诺伊大学（Southern Illinois University）通信文学学士学位。
- Brian Murphy,has served as Nanovibronix, Inc. chief executive officer and director since October 2016. Mr. Murphy has over 25 years of senior sales, operations and general management experience in medical device and medical technology companies, including ATI Medical Equipment Corporation, Mountain Medical Equipment Inc. and Healthdyne Technologies Inc. From 2012 to 2016, Mr. Murphy served in various roles at MiMedx Group, Inc., where he initiated and managed the commercial sales and national accounts efforts within the advanced wound care segment. From 2010 to 2012, Mr. Murphy was the chief executive officer of O2 Insights, Inc., a start-up wound care diagnostics company, and led the sale of the company to Systagenix Ltd. in June 2012. From 2008 to 2010, Mr. Murphy served as vice president of sales for ConvaTec and led the negative pressure wound therapy business. From 1992 to 2008, Mr. Murphy served a total of 17 years at Kinetic Concepts, Inc. (KCI) in various positions overseeing sales, operations and general management. Mr. Murphy holds a bachelor of arts degree in communications from Southern Illinois University.
- Christopher Fashek
-
Christopher Fashek自2016年11月起担任我们的董事兼董事长。法舍克先生是一位有成就的梦百合执行官，在全球领先的医疗设备和制药企业方面有着良好的记录。Fashek先生领导的团队向临床社区和严重或复杂伤口的患者介绍了V.A.C.&174；疗法，一种负压伤口疗法。从2018年6月起，Fashek先生担任Brain Sentinel，Inc.的首席执行官兼董事。2016年7月至2017年6月，法舍克先生担任Atteris梦百合，LLC.的首席执行官。Fashek先生目前担任Rochal Industries LLC的副董事长，并担任World CranioFace Foundation WCF和IDN Summit的董事。从1995年到2007年，他曾任职KCI公司，担任KCI USA的副主席、首席执行官和总裁。从2008年到2011年他是Systegenix，Ltd.的董事会主席。从2014年到2015年，他曾担任Spiracur公司的董事会主席兼首席执行官。他目前担任MedTech Solutions Group，LLC（德克萨斯州圣安东尼奥的初创公司）的主席。他获有Upsala College文学学士学位和Fairleigh Dickinson University工商管理硕士学位。
Christopher Fashek,has served as Nanovibronix, Inc. director and Chairman of the Board since November 2016. Mr. Fashek is an accomplished healthcare executive with a record of leading global medical-device and pharmaceutical businesses. Mr. Fashek led the team that introduced V.A.C. therapy, a negative pressure wound therapy, to both the clinical community, and patients with serious or complex wounds. From June 2018, to 2020, Mr. Fashek has served as Chief Executive Officer and Director of Brain Sentinel, Inc. Mr. Fashek currently serves as a Director of World Craniofacial Foundation (WCF), the Wound Healing Foundation (WHF), and the American College of Wound Healing and Tissue Repair (ACWHTR). From 1995 to 2007, he was at KCI as the Vice Chairman, Chief Executive Officer, and President of KCI USA. From 2008 to 2011, he was the Chairman of the Board of Directors at Systagenix, Ltd. From 2014 to 2015, he was the Chairman of the Board of Directors and Chief Executive Officer of Spiracur, Inc. He currently serves as Chairman of MedTech Solutions Group, LLC, a startup in San Antonio, Texas. He has a Bachelor of Arts degree from Upsala College and Master of Business Administration from Fairleigh Dickinson University. - Christopher Fashek自2016年11月起担任我们的董事兼董事长。法舍克先生是一位有成就的梦百合执行官，在全球领先的医疗设备和制药企业方面有着良好的记录。Fashek先生领导的团队向临床社区和严重或复杂伤口的患者介绍了V.A.C.&174；疗法，一种负压伤口疗法。从2018年6月起，Fashek先生担任Brain Sentinel，Inc.的首席执行官兼董事。2016年7月至2017年6月，法舍克先生担任Atteris梦百合，LLC.的首席执行官。Fashek先生目前担任Rochal Industries LLC的副董事长，并担任World CranioFace Foundation WCF和IDN Summit的董事。从1995年到2007年，他曾任职KCI公司，担任KCI USA的副主席、首席执行官和总裁。从2008年到2011年他是Systegenix，Ltd.的董事会主席。从2014年到2015年，他曾担任Spiracur公司的董事会主席兼首席执行官。他目前担任MedTech Solutions Group，LLC（德克萨斯州圣安东尼奥的初创公司）的主席。他获有Upsala College文学学士学位和Fairleigh Dickinson University工商管理硕士学位。
- Christopher Fashek,has served as Nanovibronix, Inc. director and Chairman of the Board since November 2016. Mr. Fashek is an accomplished healthcare executive with a record of leading global medical-device and pharmaceutical businesses. Mr. Fashek led the team that introduced V.A.C. therapy, a negative pressure wound therapy, to both the clinical community, and patients with serious or complex wounds. From June 2018, to 2020, Mr. Fashek has served as Chief Executive Officer and Director of Brain Sentinel, Inc. Mr. Fashek currently serves as a Director of World Craniofacial Foundation (WCF), the Wound Healing Foundation (WHF), and the American College of Wound Healing and Tissue Repair (ACWHTR). From 1995 to 2007, he was at KCI as the Vice Chairman, Chief Executive Officer, and President of KCI USA. From 2008 to 2011, he was the Chairman of the Board of Directors at Systagenix, Ltd. From 2014 to 2015, he was the Chairman of the Board of Directors and Chief Executive Officer of Spiracur, Inc. He currently serves as Chairman of MedTech Solutions Group, LLC, a startup in San Antonio, Texas. He has a Bachelor of Arts degree from Upsala College and Master of Business Administration from Fairleigh Dickinson University.
- Martin Goldstein
-
Martin Goldstein自2015年3月25日以来一直担任我们的董事，并已从事泌尿科执业20多年，在结石疾病的管理方面具有特殊的专业知识。戈尔茨坦博士是一位有成就的梦百合企业家。他是New Jersey Urology（全国最大的泌尿外科集团实践）的总裁。他也担任Urology Management Associates公司（私人股本支持的实体，为独立泌尿外科集团提供行政实践管理服务）的公司开发和收购的高级副总裁。Goldstein博士是大都会外科中心（Metropolitan Surgery Center）的联合创始人和执行董事会成员，这是一家大型多专科门诊外科中心。
Martin Goldstein,has served as Nanovibronix, Inc. director since March 25, 2015 and is on Nanovibronix, Inc. Corporate Governance Committee. He has been a practicing urologist for more than 20 years and is also an accomplished healthcare entrepreneur. For more than ten years Dr Goldstein presided over New Jersey Urology, one the largest urology group practices in the country. As President, he successfully navigated New Jersey Urology through two private equity transactions and the subsequent acquisition by Village MD. He now serves as the National Urology Service Line Chief for Village MD/Summit Health, a Walgreens & Cigna backed healthcare company. Previously, he served as Senior Vice President of Corporate Development and Acquisitions of Urology Management Associates, a private equity backed entity providing administrative practice management services to independent urology groups. Dr. Goldstein is a co-founder and executive board member of Metropolitan Surgery Center, a large multispecialty ambulatory surgery center. - Martin Goldstein自2015年3月25日以来一直担任我们的董事，并已从事泌尿科执业20多年，在结石疾病的管理方面具有特殊的专业知识。戈尔茨坦博士是一位有成就的梦百合企业家。他是New Jersey Urology（全国最大的泌尿外科集团实践）的总裁。他也担任Urology Management Associates公司（私人股本支持的实体，为独立泌尿外科集团提供行政实践管理服务）的公司开发和收购的高级副总裁。Goldstein博士是大都会外科中心（Metropolitan Surgery Center）的联合创始人和执行董事会成员，这是一家大型多专科门诊外科中心。
- Martin Goldstein,has served as Nanovibronix, Inc. director since March 25, 2015 and is on Nanovibronix, Inc. Corporate Governance Committee. He has been a practicing urologist for more than 20 years and is also an accomplished healthcare entrepreneur. For more than ten years Dr Goldstein presided over New Jersey Urology, one the largest urology group practices in the country. As President, he successfully navigated New Jersey Urology through two private equity transactions and the subsequent acquisition by Village MD. He now serves as the National Urology Service Line Chief for Village MD/Summit Health, a Walgreens & Cigna backed healthcare company. Previously, he served as Senior Vice President of Corporate Development and Acquisitions of Urology Management Associates, a private equity backed entity providing administrative practice management services to independent urology groups. Dr. Goldstein is a co-founder and executive board member of Metropolitan Surgery Center, a large multispecialty ambulatory surgery center.
- Michael Ferguson
-
Michael Ferguson自2015年4月27日起担任我们的董事。Ferguson先生目前是BakerHostetler的高级顾问，担任他们联邦政策团队的领导。他于2009年1月创立Ferguson Strategies公司（政府事务和战略业务咨询公司），在那里他曾担任首席执行官兼主席。从2001年到2009年1月，他曾任职美国众议院，代表新泽西州第七国会选区。在国会期间，他是众议院能源和商业委员会的成员，该委员会对梦百合、电信和能源行业拥有广泛的管辖权。他曾担任the Panel&8217；s Health Subscription的副主席，在那里他成为医疗保健问题的关键成员，并于2003年帮助确保Medicare Part D处方药福利的通过。此外，他曾担任电信和互联网小组委员会以及监督和调查小组委员会的成员。Ferguson先生也是众议院金融服务委员会（House Financial Services Committee）的成员，在那里他共同赞助了2002年的《萨班斯-奥克斯利法案》（Sarbanes-Oxley Act of2002），并帮助制定了最初的恐怖主义风险保险法。Ferguson先生是新泽西州体育和展览管理局（New Jersey Sports and Exhibition Authority）的前专员委员会主席，也担任公共利益医疗中心（Center for Medicine in the Public Interest’；S Odyssey Initiative）的生物医学创新与人类健康高级研究员。他也曾任职于各种公司咨询董事会和委员会，包括Pfizer，Inc.、the National Italian American Foundation和the United States Golf Association。Ferguson先生在圣母大学（University of Notre Dame）获得政府学学士学位，并在乔治敦大学（Georgetown University）获得公共政策硕士学位，专攻教育政策。
Michael Ferguson,has served as Nanovibronix, Inc. director since April 27, 2015. Since November 2023, Mr. Ferguson has served as executive vice president for federal legislative relations at AT&T. In addition, Mr. Ferguson founded Ferguson Strategies, LLC, a government affairs and strategic business consulting firm, where he served as the chief executive officer and chairman. Before joining AT&T, Mr. Ferguson served as a senior advisor at BakerHostetler, serving as the leader of their Federal Policy team. In January 2009, From 2001 to January 2009, he served in the U.S. House of Representatives, representing New Jersey's 7th congressional district. While in Congress, he was a member of the House Energy and Commerce Committee, which has wide jurisdiction over the healthcare, telecommunications and energy industries. He served as vice chairman of the panel's Health Subcommittee, where he became a key member on health care issues and helped to ensure passage of the Medicare Part D prescription drug benefit in 2003. In addition, he served as a member of the Telecommunications and Internet Subcommittee as well as the Oversight and Investigations Subcommittee. Mr. Ferguson was also a member of the House Financial Services Committee, where he cosponsored the Sarbanes-Oxley Act of 2002 and helped enact the initial terrorism risk insurance law. Mr. Ferguson was the former chairman of the Board of Commissioners of the New Jersey Sports and Exhibition Authority and also serves as a senior fellow of the Center for Medicine in the Public Interest's Odyssey Initiative for Biomedical Innovation and Human Health. He has also served on various corporate advisory boards and committees, including for Pfizer, Inc., the National Italian American Foundation and the United States Golf Association. Mr. Ferguson received a bachelor's degree in government from the University of Notre Dame and a master's of public policy degree with a specialization in education policy from Georgetown University. - Michael Ferguson自2015年4月27日起担任我们的董事。Ferguson先生目前是BakerHostetler的高级顾问，担任他们联邦政策团队的领导。他于2009年1月创立Ferguson Strategies公司（政府事务和战略业务咨询公司），在那里他曾担任首席执行官兼主席。从2001年到2009年1月，他曾任职美国众议院，代表新泽西州第七国会选区。在国会期间，他是众议院能源和商业委员会的成员，该委员会对梦百合、电信和能源行业拥有广泛的管辖权。他曾担任the Panel&8217；s Health Subscription的副主席，在那里他成为医疗保健问题的关键成员，并于2003年帮助确保Medicare Part D处方药福利的通过。此外，他曾担任电信和互联网小组委员会以及监督和调查小组委员会的成员。Ferguson先生也是众议院金融服务委员会（House Financial Services Committee）的成员，在那里他共同赞助了2002年的《萨班斯-奥克斯利法案》（Sarbanes-Oxley Act of2002），并帮助制定了最初的恐怖主义风险保险法。Ferguson先生是新泽西州体育和展览管理局（New Jersey Sports and Exhibition Authority）的前专员委员会主席，也担任公共利益医疗中心（Center for Medicine in the Public Interest’；S Odyssey Initiative）的生物医学创新与人类健康高级研究员。他也曾任职于各种公司咨询董事会和委员会，包括Pfizer，Inc.、the National Italian American Foundation和the United States Golf Association。Ferguson先生在圣母大学（University of Notre Dame）获得政府学学士学位，并在乔治敦大学（Georgetown University）获得公共政策硕士学位，专攻教育政策。
- Michael Ferguson,has served as Nanovibronix, Inc. director since April 27, 2015. Since November 2023, Mr. Ferguson has served as executive vice president for federal legislative relations at AT&T. In addition, Mr. Ferguson founded Ferguson Strategies, LLC, a government affairs and strategic business consulting firm, where he served as the chief executive officer and chairman. Before joining AT&T, Mr. Ferguson served as a senior advisor at BakerHostetler, serving as the leader of their Federal Policy team. In January 2009, From 2001 to January 2009, he served in the U.S. House of Representatives, representing New Jersey's 7th congressional district. While in Congress, he was a member of the House Energy and Commerce Committee, which has wide jurisdiction over the healthcare, telecommunications and energy industries. He served as vice chairman of the panel's Health Subcommittee, where he became a key member on health care issues and helped to ensure passage of the Medicare Part D prescription drug benefit in 2003. In addition, he served as a member of the Telecommunications and Internet Subcommittee as well as the Oversight and Investigations Subcommittee. Mr. Ferguson was also a member of the House Financial Services Committee, where he cosponsored the Sarbanes-Oxley Act of 2002 and helped enact the initial terrorism risk insurance law. Mr. Ferguson was the former chairman of the Board of Commissioners of the New Jersey Sports and Exhibition Authority and also serves as a senior fellow of the Center for Medicine in the Public Interest's Odyssey Initiative for Biomedical Innovation and Human Health. He has also served on various corporate advisory boards and committees, including for Pfizer, Inc., the National Italian American Foundation and the United States Golf Association. Mr. Ferguson received a bachelor's degree in government from the University of Notre Dame and a master's of public policy degree with a specialization in education policy from Georgetown University.
- Aurora Cassirer
-
Aurora Cassirer自2022年1月起担任NanoVibronix, Inc.的董事，并参与NanoVibronix, Inc.的公司治理以及NanoVibronix, Inc.的薪酬委员会。她是一位经验丰富的律师，目前在Fisher Broyles律师事务所商业诉讼科执业。她曾在其他知名律师事务所担任合伙人30多年，包括在Troutman Pepper，她曾在执行和薪酬委员会任职，并管理纽约办事处多年。Cassirer女士有一个专注于商业诉讼和公司治理问题的复杂实践。她在处理公共和私人持有的生物技术/健康技术和生物制药公司方面发展了一个特殊的利基市场。在过去的20年里，卡西尔女士一直被Martindale-Hubbell评为AV杰出人物，自2008年以来，她每年都被《法律与政治》杂志评为纽约商业诉讼领域杰出律师。在此之前，她曾担任ReferWell，f/k/a Urgent Consult，LLC咨询委员会主席，该公司是一家医疗技术行业的初创企业，目前担任Live Care LLC咨询委员会成员，该公司是一家从事远程监测病人的初创企业。她还在儿童需要防御Kind的董事会任职，这是一个非营利组织，她是该组织薪酬委员会的成员。她还是耶路撒冷技术学院之友委员会的成员，并在其发展委员会任职。她目前担任纽约州律师协会国际公司合规委员会的联合主席。Cassirer女士的JD是从纽约大学获得的。
Aurora Cassirer,has served as Nanovibronix, Inc. director since January 2022 and is on Nanovibronix, Inc. corporate governance and Nanovibronix, Inc. compensation committees. She is a highly experienced attorney, currently practicing at Fisher Broyles LLP in the Business Litigation Section. She has previously served as a partner in other prominent law firms for more than 30 years, including at Troutman Pepper, where she served on the Executive and Compensation Committee and managed the New York office for a number of years. Ms. Cassirer has a sophisticated practice focusing on business litigation and corporate governance issues. She has developed a particular niche in dealing with publicly and privately held biotech/healthtech and biopharma companies. Ms. Cassirer has been listed as AV Preeminent by Martindale-Hubbell consistently for the last 20 years as well as being listed in Law & Politics' New York Super Lawyers for excellence in Business Litigation every year since 2008. Previously, she served as Chair of the Advisory Board of ReferWell, f/k/a Urgent Consult, LLC, a start-up in the health tech business, and currently serves on the Advisory Board of Live Care LLC , a start-up engaged in the remote monitoring of patients. She also serves on the Board of Directors of Kids in Need of Defense (KIND), a not-for-profit organization where she is on its Compensation Committee. She is also a member of the Board of Friends of Jerusalem College of Technology and serves on its Development Committee. She currently serves as co-chair of the New York State Bar Association International Corporate Compliance Committee . Ms. Cassirer received her JD from New York University. - Aurora Cassirer自2022年1月起担任NanoVibronix, Inc.的董事，并参与NanoVibronix, Inc.的公司治理以及NanoVibronix, Inc.的薪酬委员会。她是一位经验丰富的律师，目前在Fisher Broyles律师事务所商业诉讼科执业。她曾在其他知名律师事务所担任合伙人30多年，包括在Troutman Pepper，她曾在执行和薪酬委员会任职，并管理纽约办事处多年。Cassirer女士有一个专注于商业诉讼和公司治理问题的复杂实践。她在处理公共和私人持有的生物技术/健康技术和生物制药公司方面发展了一个特殊的利基市场。在过去的20年里，卡西尔女士一直被Martindale-Hubbell评为AV杰出人物，自2008年以来，她每年都被《法律与政治》杂志评为纽约商业诉讼领域杰出律师。在此之前，她曾担任ReferWell，f/k/a Urgent Consult，LLC咨询委员会主席，该公司是一家医疗技术行业的初创企业，目前担任Live Care LLC咨询委员会成员，该公司是一家从事远程监测病人的初创企业。她还在儿童需要防御Kind的董事会任职，这是一个非营利组织，她是该组织薪酬委员会的成员。她还是耶路撒冷技术学院之友委员会的成员，并在其发展委员会任职。她目前担任纽约州律师协会国际公司合规委员会的联合主席。Cassirer女士的JD是从纽约大学获得的。
- Aurora Cassirer,has served as Nanovibronix, Inc. director since January 2022 and is on Nanovibronix, Inc. corporate governance and Nanovibronix, Inc. compensation committees. She is a highly experienced attorney, currently practicing at Fisher Broyles LLP in the Business Litigation Section. She has previously served as a partner in other prominent law firms for more than 30 years, including at Troutman Pepper, where she served on the Executive and Compensation Committee and managed the New York office for a number of years. Ms. Cassirer has a sophisticated practice focusing on business litigation and corporate governance issues. She has developed a particular niche in dealing with publicly and privately held biotech/healthtech and biopharma companies. Ms. Cassirer has been listed as AV Preeminent by Martindale-Hubbell consistently for the last 20 years as well as being listed in Law & Politics' New York Super Lawyers for excellence in Business Litigation every year since 2008. Previously, she served as Chair of the Advisory Board of ReferWell, f/k/a Urgent Consult, LLC, a start-up in the health tech business, and currently serves on the Advisory Board of Live Care LLC , a start-up engaged in the remote monitoring of patients. She also serves on the Board of Directors of Kids in Need of Defense (KIND), a not-for-profit organization where she is on its Compensation Committee. She is also a member of the Board of Friends of Jerusalem College of Technology and serves on its Development Committee. She currently serves as co-chair of the New York State Bar Association International Corporate Compliance Committee . Ms. Cassirer received her JD from New York University.
- Maria Schroeder
-
Maria Schroeder自2022年1月起担任NanoVibronix, Inc.的董事。Schroeder女士曾在多家上市公司和私营公司担任重要的财务主管，包括CST Brands、KCI和Brain Sentinel，最近她担任这些公司的Chief Financial Officer。在加入Brain Sentinel之前，施罗德女士曾担任CST Brands全球税务副总裁。CST Brands是一家财富250强零售石油和天然气公司。在此之前，她曾担任Kinetic Concepts，Inc.的副总裁兼财务主管兼税务主管。KCI是一家价值15亿美元的医疗技术公司，最近被3M以67亿美元的价格收购。在KCI，她在多项战略交易中担任重要角色，包括两次杠杆收购和一次首次公开募股。施罗德女士的职业生涯始于安永会计师事务所，之后加入了德勤哈斯金斯事务所。施罗德女士是圣安东尼奥商会首屈一指的领导力项目圣安东尼奥领导力的校友，曾在圣安东尼奥的德克萨斯大学审计委员会任职，担任圣安东尼奥女孩公司的财务主管，并担任圣安东尼奥公共电视台KLRN的董事会成员。Schroeder女士是一名注册会计师和特许全球管理会计师，拥有德克萨斯大学圣安东尼奥分校会计学学士学位。
Maria Schroeder,has served as Nanovibronix, Inc. director since January 2022. Ms. Schroeder has been a key Financial Executive at a number of public and privately-held companies including CST Brands, KCI and Brain Sentinel, where she recently served as Chief Financial Officer. Prior to Brain Sentinel, Ms. Schroeder served as Vice President, Global Tax of CST Brands, a Fortune 250 retail Oil and Gas company. Prior to that, she served as Vice President and Treasurer & Head of Tax at Kinetic Concepts, Inc. ("KCI") a $1.5 billion MedTech company, which was recently purchased by 3M for $6.7 billion. At KCI, she held key roles in a number of strategic transactions, including two leveraged buyouts and an initial public offering. Ms. Schroeder began her career at Ernst & Whinney before joining Deloitte Haskins & Sells. Ms. Schroeder is an alumnus of San Antonio Leadership, a premier leadership program of the San Antonio Chamber of Commerce and has served on the Audit Committee for The University of Texas at San Antonio, as Treasurer of Girls, Inc. of San Antonio and as a board member of KLRN, San Antonio's public television station. Ms. Schroeder is a Certified Public Accountant and Chartered Global Management Accountant with a B.B.A. in Accounting from the University of Texas at San Antonio. - Maria Schroeder自2022年1月起担任NanoVibronix, Inc.的董事。Schroeder女士曾在多家上市公司和私营公司担任重要的财务主管，包括CST Brands、KCI和Brain Sentinel，最近她担任这些公司的Chief Financial Officer。在加入Brain Sentinel之前，施罗德女士曾担任CST Brands全球税务副总裁。CST Brands是一家财富250强零售石油和天然气公司。在此之前，她曾担任Kinetic Concepts，Inc.的副总裁兼财务主管兼税务主管。KCI是一家价值15亿美元的医疗技术公司，最近被3M以67亿美元的价格收购。在KCI，她在多项战略交易中担任重要角色，包括两次杠杆收购和一次首次公开募股。施罗德女士的职业生涯始于安永会计师事务所，之后加入了德勤哈斯金斯事务所。施罗德女士是圣安东尼奥商会首屈一指的领导力项目圣安东尼奥领导力的校友，曾在圣安东尼奥的德克萨斯大学审计委员会任职，担任圣安东尼奥女孩公司的财务主管，并担任圣安东尼奥公共电视台KLRN的董事会成员。Schroeder女士是一名注册会计师和特许全球管理会计师，拥有德克萨斯大学圣安东尼奥分校会计学学士学位。
- Maria Schroeder,has served as Nanovibronix, Inc. director since January 2022. Ms. Schroeder has been a key Financial Executive at a number of public and privately-held companies including CST Brands, KCI and Brain Sentinel, where she recently served as Chief Financial Officer. Prior to Brain Sentinel, Ms. Schroeder served as Vice President, Global Tax of CST Brands, a Fortune 250 retail Oil and Gas company. Prior to that, she served as Vice President and Treasurer & Head of Tax at Kinetic Concepts, Inc. ("KCI") a $1.5 billion MedTech company, which was recently purchased by 3M for $6.7 billion. At KCI, she held key roles in a number of strategic transactions, including two leveraged buyouts and an initial public offering. Ms. Schroeder began her career at Ernst & Whinney before joining Deloitte Haskins & Sells. Ms. Schroeder is an alumnus of San Antonio Leadership, a premier leadership program of the San Antonio Chamber of Commerce and has served on the Audit Committee for The University of Texas at San Antonio, as Treasurer of Girls, Inc. of San Antonio and as a board member of KLRN, San Antonio's public television station. Ms. Schroeder is a Certified Public Accountant and Chartered Global Management Accountant with a B.B.A. in Accounting from the University of Texas at San Antonio.
- Thomas R. Mika
-
Thomas R. Mika自2015年4月27日起担任NanoVibronix, Inc.的董事。Mika先生拥有30多年的高级管理、财务和咨询经验。Mika先生目前在POET Technologies，Inc.（多伦多证券交易所代码：PTK，纳斯达克代码：POET）担任执行副总裁兼首席财务官，此前曾担任Rennova Health, Inc.（纳斯达克代码：RNVA）的Shlomo Kramer以及其全资子公司CollabRx，Inc.（纳斯达克代码：CLRX）的首席执行官。Rennova Health是一家垂直整合的公立医疗保健控股公司，于2015年11月与CollabRx合并，并在纳斯达克上市。CollabRx前身为Tegal公司（纳斯达克股票代码：TGAL），是一家临床决策支持公司，提供精准肿瘤学和基因组医学方面的专家解决方案。Mika先生自2005年3月起担任CollabRx及其前身公司的董事长兼首席执行官。从1992年至2002年，Mika先生在公司董事会任职，包括担任薪酬委员会主席和审计委员会成员。此前，Mika与他人共同创立了IMTEC，这是一家精品投资和咨询公司，其重点领域包括医疗保健、制药、媒体和信息技术。作为IMTEC的合作伙伴，Mika先生在20年的时间里为美国、欧洲和日本的客户提供服务，在多个企业中担任首席执行官。在他职业生涯的早期，米卡是Cresap，McCormick & Paget的管理顾问和国家科学基金会的政策分析师。Mika先生拥有伊利诺伊大学香槟分校微生物学理学学士学位和哈佛大学商学院工商管理硕士学位。
Thomas R. Mika,has served as Nanovibronix, Inc. director since April 27, 2015. Mr. Mika has over 30 years of senior management, finance and consulting experience. Mr. Mika is currently executive vice president and chief financial officer of POET Technologies, Inc. (TSX Venture: PTK, NASDAQ:POET) and previously served as as chief executive officer of CollabRx, Inc. (NASDAQ: CLRX) and its predecessor, Tegal Corporation (NASDAQ: TGAL). CollabRx was a pioneer in clinical decision-support and precision oncology based on genomic testing. Mr. Mika was the chairman and chief executive officer of Tegal since March 2005 which became CollabRx in 2012, and served as its Chief Financial Officer since 2002. From 1992 to 2002, Mr. Mika served on the company's Board, which included periods of service as the chairman of the compensation committee and a member of the audit committee. Previously, Mr. Mika co-founded IMTEC, a boutique investment and consulting firm whose areas of focus included health care, pharmaceuticals, media and information technology. As a partner of IMTEC, Mr. Mika served clients in the United States, Europe and Japan over a period of 20 years, taking on the role of chief executive officer in several ventures. Earlier in his career, Mr. Mika was a managing consultant with Cresap, McCormick & Paget and a policy analyst for the National Science Foundation. Mr. Mika holds a bachelor of science degree in Microbiology from the University of Illinois at Urbana-Champaign and a master of business administration degree from the Harvard Graduate School of Business. - Thomas R. Mika自2015年4月27日起担任NanoVibronix, Inc.的董事。Mika先生拥有30多年的高级管理、财务和咨询经验。Mika先生目前在POET Technologies，Inc.（多伦多证券交易所代码：PTK，纳斯达克代码：POET）担任执行副总裁兼首席财务官，此前曾担任Rennova Health, Inc.（纳斯达克代码：RNVA）的Shlomo Kramer以及其全资子公司CollabRx，Inc.（纳斯达克代码：CLRX）的首席执行官。Rennova Health是一家垂直整合的公立医疗保健控股公司，于2015年11月与CollabRx合并，并在纳斯达克上市。CollabRx前身为Tegal公司（纳斯达克股票代码：TGAL），是一家临床决策支持公司，提供精准肿瘤学和基因组医学方面的专家解决方案。Mika先生自2005年3月起担任CollabRx及其前身公司的董事长兼首席执行官。从1992年至2002年，Mika先生在公司董事会任职，包括担任薪酬委员会主席和审计委员会成员。此前，Mika与他人共同创立了IMTEC，这是一家精品投资和咨询公司，其重点领域包括医疗保健、制药、媒体和信息技术。作为IMTEC的合作伙伴，Mika先生在20年的时间里为美国、欧洲和日本的客户提供服务，在多个企业中担任首席执行官。在他职业生涯的早期，米卡是Cresap，McCormick & Paget的管理顾问和国家科学基金会的政策分析师。Mika先生拥有伊利诺伊大学香槟分校微生物学理学学士学位和哈佛大学商学院工商管理硕士学位。
- Thomas R. Mika,has served as Nanovibronix, Inc. director since April 27, 2015. Mr. Mika has over 30 years of senior management, finance and consulting experience. Mr. Mika is currently executive vice president and chief financial officer of POET Technologies, Inc. (TSX Venture: PTK, NASDAQ:POET) and previously served as as chief executive officer of CollabRx, Inc. (NASDAQ: CLRX) and its predecessor, Tegal Corporation (NASDAQ: TGAL). CollabRx was a pioneer in clinical decision-support and precision oncology based on genomic testing. Mr. Mika was the chairman and chief executive officer of Tegal since March 2005 which became CollabRx in 2012, and served as its Chief Financial Officer since 2002. From 1992 to 2002, Mr. Mika served on the company's Board, which included periods of service as the chairman of the compensation committee and a member of the audit committee. Previously, Mr. Mika co-founded IMTEC, a boutique investment and consulting firm whose areas of focus included health care, pharmaceuticals, media and information technology. As a partner of IMTEC, Mr. Mika served clients in the United States, Europe and Japan over a period of 20 years, taking on the role of chief executive officer in several ventures. Earlier in his career, Mr. Mika was a managing consultant with Cresap, McCormick & Paget and a policy analyst for the National Science Foundation. Mr. Mika holds a bachelor of science degree in Microbiology from the University of Illinois at Urbana-Champaign and a master of business administration degree from the Harvard Graduate School of Business.
- Harold Jacob
-
Harold Jacob自2014年3月1日起担任NanoVibronix, Inc.的首席医疗官，并自2003年9月起担任NanoVibronix, Inc.的董事。2003年9月至2014年2月4日，Jacob博士担任NanoVibronix, Inc.董事会主席，2003年9月至2014年3月1日，Jacob博士担任NanoVibronix, Inc.的首席执行官。Jacob博士还履行首席财务干事的职能，直至2014年4月1日。Jacob博士是NanoVibronix, Inc.的联合创始人，在医疗设备开发方面有着广泛的工作经验。Jacob博士还于2004年至2011年3月在以色列耶路撒冷的Shaare Zedek医疗中心兼职担任主治胃肠病学家。自2011年4月起，他在以色列耶路撒冷哈大沙大学医院担任消化内科主治医师。从1999年至今，Jacob博士一直担任医疗仪器开发公司的总裁，该公司为初创公司和早期公司提供咨询服务，并为自己的专利医疗设备提供专利。从1997年到2003年，Jacob博士在Given Imaging有限公司担任医疗事务主管，该公司开发了第一台用于检查肠道的可吞咽无线药丸相。Jacob博士还曾担任Oramed Pharmaceuticals Inc.的董事。Oramed Pharmaceuticals Inc.是一家专注于开发创新口服可摄取胶囊药物的制药公司。
Harold Jacob,has served as Nanovibronix, Inc. chief medical officer since March 1, 2014, and as Nanovibronix, Inc. director since September 2003. From September 2003 to February 4, 2014, Dr. Jacob served as chairman of Nanovibronix, Inc. Board and from September 2003 to March 1, 2014, Dr. Jacob served as Nanovibronix, Inc. chief executive officer. Dr. Jacob also performed the functions of a principal financial officer until April 1, 2014. Dr. Jacob is Nanovibronix, Inc. co-founder and has worked extensively in medical device development. Dr. Jacob also served part-time as an attending gastroenterologist at Shaare Zedek Medical Center in Jerusalem, Israel from 2004 to March 2011. Since April 2011, he has been an attending physician in Gastroenterology at Hadassah University Hospital in Jerusalem, Israel. From 1999 to the present, Dr. Jacob has served as the president of Medical Instrument Development Inc., which provides consulting services to start-up and early stage companies and patents its own proprietary medical devices. From 1997 to 2003, Dr. Jacob served as director of medical affairs at Given Imaging Ltd., a company that developed the first swallowable wireless pill camera for inspection of the intestines. Dr. Jacob also formerly served as a director for Oramed Pharmaceuticals Inc., a pharmaceutical company focused on the development of innovative orally ingestible capsule medication. - Harold Jacob自2014年3月1日起担任NanoVibronix, Inc.的首席医疗官，并自2003年9月起担任NanoVibronix, Inc.的董事。2003年9月至2014年2月4日，Jacob博士担任NanoVibronix, Inc.董事会主席，2003年9月至2014年3月1日，Jacob博士担任NanoVibronix, Inc.的首席执行官。Jacob博士还履行首席财务干事的职能，直至2014年4月1日。Jacob博士是NanoVibronix, Inc.的联合创始人，在医疗设备开发方面有着广泛的工作经验。Jacob博士还于2004年至2011年3月在以色列耶路撒冷的Shaare Zedek医疗中心兼职担任主治胃肠病学家。自2011年4月起，他在以色列耶路撒冷哈大沙大学医院担任消化内科主治医师。从1999年至今，Jacob博士一直担任医疗仪器开发公司的总裁，该公司为初创公司和早期公司提供咨询服务，并为自己的专利医疗设备提供专利。从1997年到2003年，Jacob博士在Given Imaging有限公司担任医疗事务主管，该公司开发了第一台用于检查肠道的可吞咽无线药丸相。Jacob博士还曾担任Oramed Pharmaceuticals Inc.的董事。Oramed Pharmaceuticals Inc.是一家专注于开发创新口服可摄取胶囊药物的制药公司。
- Harold Jacob,has served as Nanovibronix, Inc. chief medical officer since March 1, 2014, and as Nanovibronix, Inc. director since September 2003. From September 2003 to February 4, 2014, Dr. Jacob served as chairman of Nanovibronix, Inc. Board and from September 2003 to March 1, 2014, Dr. Jacob served as Nanovibronix, Inc. chief executive officer. Dr. Jacob also performed the functions of a principal financial officer until April 1, 2014. Dr. Jacob is Nanovibronix, Inc. co-founder and has worked extensively in medical device development. Dr. Jacob also served part-time as an attending gastroenterologist at Shaare Zedek Medical Center in Jerusalem, Israel from 2004 to March 2011. Since April 2011, he has been an attending physician in Gastroenterology at Hadassah University Hospital in Jerusalem, Israel. From 1999 to the present, Dr. Jacob has served as the president of Medical Instrument Development Inc., which provides consulting services to start-up and early stage companies and patents its own proprietary medical devices. From 1997 to 2003, Dr. Jacob served as director of medical affairs at Given Imaging Ltd., a company that developed the first swallowable wireless pill camera for inspection of the intestines. Dr. Jacob also formerly served as a director for Oramed Pharmaceuticals Inc., a pharmaceutical company focused on the development of innovative orally ingestible capsule medication.
高管简历
中英对照 | 中文 | 英文- Brian Murphy
Brian Murphy自2016年10月起担任我们的首席执行官兼董事。Murphy先生在医疗设备和医疗技术公司拥有超过25年的高级销售，运营和一般管理经验，包括ATI Medical Equipment Corporation，Mountain Medical Equipment Inc.和Healthdyne Technologies Inc.。从2012年到2016年，墨菲先生在MimedxGroup，Inc.担任过各种职务，在那里他发起并管理高级伤口护理部门的商业销售和国民账户工作。Murphy从2010年到2012年担任O2Insights，Inc.（一家初创伤口护理诊断公司）首席执行官，2012年6月领导公司出售给Systegenix Ltd.。Murphy从2008年到2010年担任Convatec销售Vice President，领导负压伤口治疗业务。从1992年到2008年，墨菲先生在KineticConcepts，Inc.总共服务了17年KCI担任多个职位，监督销售、运营和综合管理。Murphy先生持有南伊利诺伊大学（Southern Illinois University）通信文学学士学位。
Brian Murphy,has served as Nanovibronix, Inc. chief executive officer and director since October 2016. Mr. Murphy has over 25 years of senior sales, operations and general management experience in medical device and medical technology companies, including ATI Medical Equipment Corporation, Mountain Medical Equipment Inc. and Healthdyne Technologies Inc. From 2012 to 2016, Mr. Murphy served in various roles at MiMedx Group, Inc., where he initiated and managed the commercial sales and national accounts efforts within the advanced wound care segment. From 2010 to 2012, Mr. Murphy was the chief executive officer of O2 Insights, Inc., a start-up wound care diagnostics company, and led the sale of the company to Systagenix Ltd. in June 2012. From 2008 to 2010, Mr. Murphy served as vice president of sales for ConvaTec and led the negative pressure wound therapy business. From 1992 to 2008, Mr. Murphy served a total of 17 years at Kinetic Concepts, Inc. (KCI) in various positions overseeing sales, operations and general management. Mr. Murphy holds a bachelor of arts degree in communications from Southern Illinois University.- Brian Murphy自2016年10月起担任我们的首席执行官兼董事。Murphy先生在医疗设备和医疗技术公司拥有超过25年的高级销售，运营和一般管理经验，包括ATI Medical Equipment Corporation，Mountain Medical Equipment Inc.和Healthdyne Technologies Inc.。从2012年到2016年，墨菲先生在MimedxGroup，Inc.担任过各种职务，在那里他发起并管理高级伤口护理部门的商业销售和国民账户工作。Murphy从2010年到2012年担任O2Insights，Inc.（一家初创伤口护理诊断公司）首席执行官，2012年6月领导公司出售给Systegenix Ltd.。Murphy从2008年到2010年担任Convatec销售Vice President，领导负压伤口治疗业务。从1992年到2008年，墨菲先生在KineticConcepts，Inc.总共服务了17年KCI担任多个职位，监督销售、运营和综合管理。Murphy先生持有南伊利诺伊大学（Southern Illinois University）通信文学学士学位。
- Brian Murphy,has served as Nanovibronix, Inc. chief executive officer and director since October 2016. Mr. Murphy has over 25 years of senior sales, operations and general management experience in medical device and medical technology companies, including ATI Medical Equipment Corporation, Mountain Medical Equipment Inc. and Healthdyne Technologies Inc. From 2012 to 2016, Mr. Murphy served in various roles at MiMedx Group, Inc., where he initiated and managed the commercial sales and national accounts efforts within the advanced wound care segment. From 2010 to 2012, Mr. Murphy was the chief executive officer of O2 Insights, Inc., a start-up wound care diagnostics company, and led the sale of the company to Systagenix Ltd. in June 2012. From 2008 to 2010, Mr. Murphy served as vice president of sales for ConvaTec and led the negative pressure wound therapy business. From 1992 to 2008, Mr. Murphy served a total of 17 years at Kinetic Concepts, Inc. (KCI) in various positions overseeing sales, operations and general management. Mr. Murphy holds a bachelor of arts degree in communications from Southern Illinois University.
- Stephen Brown
Stephen Brown，首席财务官。布朗先生自2015年2月3日起担任我们的首席财务官。Brown自2009年起担任McGuffin Group Financial（一家金融咨询公司，专注于为早期公司提供建议，包括GMA Fund LLC、E-Prodigy Financial，LLC和The YGM Group，LLC）管理合伙人。2017年5月，布朗先生加入IDW Media Holdings，Inc.的董事会。Brown自2009年起担任Brown，Brown and Associates会计和税务实践合伙人。从1995年4月到2009年1月，布朗先生在纽约证券交易所上市的电信公司万威公司担任过多个高管职位，包括首席财务官。在此期间，Brown先生还在IDT&8217；的董事会任职了六年，并在Net2Phone Inc.的董事会任职了五年。Brown先生也是IDT Entertainment Inc.的创始人和董事长，这是一家电影工作室和媒体子公司。Brown先生是一名注册会计师和电视艺术与科学学院（Academy of Television Arts and Sciences）的成员，并在几家教育机构的董事会任职，包括在图罗学院（Touro College）的董事会任职。
Stephen Brown,has served as Nanovibronix, Inc. chief financial officer since October 5, 2020. Previously, Mr. Brown served as the Company's Chief Financial Officer from February 3, 2015 through April 30, 2019 and continued to serve as a financial consultant for the Company until his appointment as Chief Financial Officer on October 5, 2020. Mr. Brown previously served as Chief Financial Officer for IDT Corporation (NYSE: IDT) from April 1995 to January 2009, during which time he oversaw the initial public offering of a start-up telecommunications company and guided it through the spin-offs of two subsidiaries, various public offerings and bank facilities. During his tenure at IDT, Mr. Brown also served on IDT's board of directors for six years and on the board of directors of Net2Phone Inc. for five years. Mr. Brown was also the founder and chairman of IDT Entertainment Inc., a movie studio and media subsidiary of IDT. From 2009 to the present, Mr. Brown has served as a managing partner of The Mcguffin Group Financial, a financial and business consulting firm concentrating on advising early stage and micro-cap companies. He is also a partner in an accounting and tax practice, Brown, Brown and Associates. Mr. Brown was formerly a certified public accountant, is a member of the Academy of Television Arts and Sciences and serves on the board of directors for several educational institutions, including on the Board of Governors for Touro College.- Stephen Brown，首席财务官。布朗先生自2015年2月3日起担任我们的首席财务官。Brown自2009年起担任McGuffin Group Financial（一家金融咨询公司，专注于为早期公司提供建议，包括GMA Fund LLC、E-Prodigy Financial，LLC和The YGM Group，LLC）管理合伙人。2017年5月，布朗先生加入IDW Media Holdings，Inc.的董事会。Brown自2009年起担任Brown，Brown and Associates会计和税务实践合伙人。从1995年4月到2009年1月，布朗先生在纽约证券交易所上市的电信公司万威公司担任过多个高管职位，包括首席财务官。在此期间，Brown先生还在IDT&8217；的董事会任职了六年，并在Net2Phone Inc.的董事会任职了五年。Brown先生也是IDT Entertainment Inc.的创始人和董事长，这是一家电影工作室和媒体子公司。Brown先生是一名注册会计师和电视艺术与科学学院（Academy of Television Arts and Sciences）的成员，并在几家教育机构的董事会任职，包括在图罗学院（Touro College）的董事会任职。
- Stephen Brown,has served as Nanovibronix, Inc. chief financial officer since October 5, 2020. Previously, Mr. Brown served as the Company's Chief Financial Officer from February 3, 2015 through April 30, 2019 and continued to serve as a financial consultant for the Company until his appointment as Chief Financial Officer on October 5, 2020. Mr. Brown previously served as Chief Financial Officer for IDT Corporation (NYSE: IDT) from April 1995 to January 2009, during which time he oversaw the initial public offering of a start-up telecommunications company and guided it through the spin-offs of two subsidiaries, various public offerings and bank facilities. During his tenure at IDT, Mr. Brown also served on IDT's board of directors for six years and on the board of directors of Net2Phone Inc. for five years. Mr. Brown was also the founder and chairman of IDT Entertainment Inc., a movie studio and media subsidiary of IDT. From 2009 to the present, Mr. Brown has served as a managing partner of The Mcguffin Group Financial, a financial and business consulting firm concentrating on advising early stage and micro-cap companies. He is also a partner in an accounting and tax practice, Brown, Brown and Associates. Mr. Brown was formerly a certified public accountant, is a member of the Academy of Television Arts and Sciences and serves on the board of directors for several educational institutions, including on the Board of Governors for Touro College.
- Harold Jacob
Harold Jacob自2014年3月1日起担任NanoVibronix, Inc.的首席医疗官，并自2003年9月起担任NanoVibronix, Inc.的董事。2003年9月至2014年2月4日，Jacob博士担任NanoVibronix, Inc.董事会主席，2003年9月至2014年3月1日，Jacob博士担任NanoVibronix, Inc.的首席执行官。Jacob博士还履行首席财务干事的职能，直至2014年4月1日。Jacob博士是NanoVibronix, Inc.的联合创始人，在医疗设备开发方面有着广泛的工作经验。Jacob博士还于2004年至2011年3月在以色列耶路撒冷的Shaare Zedek医疗中心兼职担任主治胃肠病学家。自2011年4月起，他在以色列耶路撒冷哈大沙大学医院担任消化内科主治医师。从1999年至今，Jacob博士一直担任医疗仪器开发公司的总裁，该公司为初创公司和早期公司提供咨询服务，并为自己的专利医疗设备提供专利。从1997年到2003年，Jacob博士在Given Imaging有限公司担任医疗事务主管，该公司开发了第一台用于检查肠道的可吞咽无线药丸相机。Jacob博士还曾担任Oramed Pharmaceuticals Inc.的董事。Oramed Pharmaceuticals Inc.是一家专注于开发创新口服可摄取胶囊药物的制药公司。
Harold Jacob,has served as Nanovibronix, Inc. chief medical officer since March 1, 2014, and as Nanovibronix, Inc. director since September 2003. From September 2003 to February 4, 2014, Dr. Jacob served as chairman of Nanovibronix, Inc. Board and from September 2003 to March 1, 2014, Dr. Jacob served as Nanovibronix, Inc. chief executive officer. Dr. Jacob also performed the functions of a principal financial officer until April 1, 2014. Dr. Jacob is Nanovibronix, Inc. co-founder and has worked extensively in medical device development. Dr. Jacob also served part-time as an attending gastroenterologist at Shaare Zedek Medical Center in Jerusalem, Israel from 2004 to March 2011. Since April 2011, he has been an attending physician in Gastroenterology at Hadassah University Hospital in Jerusalem, Israel. From 1999 to the present, Dr. Jacob has served as the president of Medical Instrument Development Inc., which provides consulting services to start-up and early stage companies and patents its own proprietary medical devices. From 1997 to 2003, Dr. Jacob served as director of medical affairs at Given Imaging Ltd., a company that developed the first swallowable wireless pill camera for inspection of the intestines. Dr. Jacob also formerly served as a director for Oramed Pharmaceuticals Inc., a pharmaceutical company focused on the development of innovative orally ingestible capsule medication.- Harold Jacob自2014年3月1日起担任NanoVibronix, Inc.的首席医疗官，并自2003年9月起担任NanoVibronix, Inc.的董事。2003年9月至2014年2月4日，Jacob博士担任NanoVibronix, Inc.董事会主席，2003年9月至2014年3月1日，Jacob博士担任NanoVibronix, Inc.的首席执行官。Jacob博士还履行首席财务干事的职能，直至2014年4月1日。Jacob博士是NanoVibronix, Inc.的联合创始人，在医疗设备开发方面有着广泛的工作经验。Jacob博士还于2004年至2011年3月在以色列耶路撒冷的Shaare Zedek医疗中心兼职担任主治胃肠病学家。自2011年4月起，他在以色列耶路撒冷哈大沙大学医院担任消化内科主治医师。从1999年至今，Jacob博士一直担任医疗仪器开发公司的总裁，该公司为初创公司和早期公司提供咨询服务，并为自己的专利医疗设备提供专利。从1997年到2003年，Jacob博士在Given Imaging有限公司担任医疗事务主管，该公司开发了第一台用于检查肠道的可吞咽无线药丸相机。Jacob博士还曾担任Oramed Pharmaceuticals Inc.的董事。Oramed Pharmaceuticals Inc.是一家专注于开发创新口服可摄取胶囊药物的制药公司。
- Harold Jacob,has served as Nanovibronix, Inc. chief medical officer since March 1, 2014, and as Nanovibronix, Inc. director since September 2003. From September 2003 to February 4, 2014, Dr. Jacob served as chairman of Nanovibronix, Inc. Board and from September 2003 to March 1, 2014, Dr. Jacob served as Nanovibronix, Inc. chief executive officer. Dr. Jacob also performed the functions of a principal financial officer until April 1, 2014. Dr. Jacob is Nanovibronix, Inc. co-founder and has worked extensively in medical device development. Dr. Jacob also served part-time as an attending gastroenterologist at Shaare Zedek Medical Center in Jerusalem, Israel from 2004 to March 2011. Since April 2011, he has been an attending physician in Gastroenterology at Hadassah University Hospital in Jerusalem, Israel. From 1999 to the present, Dr. Jacob has served as the president of Medical Instrument Development Inc., which provides consulting services to start-up and early stage companies and patents its own proprietary medical devices. From 1997 to 2003, Dr. Jacob served as director of medical affairs at Given Imaging Ltd., a company that developed the first swallowable wireless pill camera for inspection of the intestines. Dr. Jacob also formerly served as a director for Oramed Pharmaceuticals Inc., a pharmaceutical company focused on the development of innovative orally ingestible capsule medication.